0       0

AMDA's 2016 Annual Conference


201 - Antipsychotic Stewardship in Long-Term Care: Mechanics and Outcomes of a Highly Successful Program


Mar 18, 2016 11:00am ‐ Mar 18, 2016 12:00pm


Credits: None available.

Standard: $24.00

Description

Accreditation Statement: AMDA – The Society for Post-Acute and Long-Term Care Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement: AMDA – The Society for Post-Acute and Long-Term Care Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABPLM Designation Statement: This internet enduring material has been pre-approved by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) for a total of 1 management hour toward certification as a Certified Medical Director (CMD) in post-acute and long-term care medicine. The CMD program is administered by the ABPLM.  Each physician should claim only those hours of credit actually spent on the activity. 

Session Description:
This session will review prevalence of behavioral and psychological symptoms of dementia (BPSD) in the long-term care setting, Centers for Medicare & Medicaid Services (CMS) regulatory standards pertinent to antipsychotic medication use in dementia care, and the National Partnership’s goals pertinent to antipsychotic medication use. Clinical vignettes will demonstrate how cultural factors of a facility influence persistence of antipsychotic medication use, and present methods to effectively address these. Objective medication criteria will be presented to start the medication (indication), to continue the medication (effectiveness), and to discontinue the medication (goal attained, lack of response, or adverse effects). Clinical vignettes will continue to demonstrate challenges and solutions. Methods to objectively and efficiently document various behaviors and their antecedents as they pertain to the use of medication will be presented. Methods and results of an award winning quality assurance and performance improvement (QAPI) program that reduced antipsychotic medications in a very large sample from 38% to 11.6% will be presented to demonstrate how initial investment of setting up trending data system yields a sustained significant improvement with minimal monitoring effort. Psychiatry’s role as an effective purveyor of a successful antipsychotic stewardship program will be demonstrated.

Learning Objective(s):

  • Discuss CMS regulatory standards pertinent to antipsychotic medications and current goals by the National Partnership to Improve Dementia Care to reduce antipsychotic medication use.
  • Assess and address the cultural factors of an institution in optimizing antipsychotic medication use.
  • Formulate objective parameters to start, continue and discontinue antipsychotic medications in the management of BPSD.
  • Describe a possible paradigm shift in the role of a psychiatrist in the LTC.
Speaker(s):
Ravindra Amin, MD
Dheeraj Mahajan, MD, CMD

Disclosure(s):
None

Reference(s):
None
 

Speaker(s):

  • Ravindra Amin, MD, Chief of Psychiatry, Coler Rehabilitation and Nursing Care Center
  • Dheeraj Mahajan, MD FACP, CMD, CIC, CHCQM, President/CEO, Chicago Internal Medicine Practice and Research (CIMPAR, SC)

Credits

  • 1.00 - Management
  • 1.00 - CME

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content